ArticleBMC pulmonary medicine2023
Analysis of clinical characteristics and prognosis of 68 patients with primary pulmonary choriocarcinoma.
Article in BMC pulmonary medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 18 citations in OpenAlex.
- Chemotherapy combined with tislelizumab for a male patient with primary pulmonary choriocarcinoma: a case report and literature review.Discover oncology · 2026Article
- Clinicopathological and molecular characteristics of primary pulmonary choriocarcinoma: a case report and systematic review.Frontiers in oncology · 2026Article
- Clinicopathological features of primary pulmonary choriocarcinoma in males: A report of two cases and literature review.Respiratory medicine case reports · 2026Article
- The role of cranial radiotherapy in managing neurological symptoms of brain metastases from pulmonary choriocarcinoma: a case report and literature review.Discover oncology · 2025Article
- A Histological Conundrum With a Distinctive Biochemical Marker: A Case Report of Primary Pulmonary Choriocarcinoma.Cureus · 2025Article
- Metastatic breast involvement from extramammary malignancies: a review of dissemination pathways, imaging features, and management strategies.La Radiologia medica · 2025Review
- Combination chemotherapy with sintilimab for treatment of a male patient with primary pulmonary choriocarcinoma: a case report and literature review.Frontiers in immunology · 2025Review
- Primary Pulmonary Choriocarcinoma With Lymph Node Metastasis: A Case Report and Brief Review.Cureus · 2024Article
- Article
- A drastic post operative course after the resection of primary pulmonary choriocarcinoma in a male.Respirology case reports · 2024Article
- Pulmonary metastatic gestational choriocarcinoma following an uncomplicated term pregnancy: a case report.Journal of medical case reports · 2024Article
- Primary mediastinal choriocarcinoma requiring differentiation from non-small cell lung cancer: An autopsy case report.Respiratory medicine case reports · 2024Article
- Case report: Molecular profiling facilitates the diagnosis of a challenging case of lung cancer with choriocarcinoma features.Frontiers in oncology · 2024Article
- Article
- Primary mediastinal choriocarcinoma in an 18-year-old male with pulmonary and brain metastasis: A case report.The clinical respiratory journal · 2023Article
- Gestational trophoblastic diseases - literature review and atypical case reports.Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologieReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
backgroundPrimary pulmonary choriocarcinoma (PPC) is a highly malignant intrapulmonary tumor with a notorious prognosis. Few clinical studies have been undertaken to investigate the clinical characteristics and prognosis of PPC. MATERIAL AND
methodsWe systematically conducted a retrospective analysis of patients with PPC in the literature published in PubMed and CNKI databases until March 31, 2022. The primary outcome was all-cause mortality. Survival curves were depicted using the Kaplan‒Meier method and compared using the stratified log-rank test. A Cox proportional hazards model was used to estimate the prognostic factors.
resultsA total of 68 patients were included, which consisted of 32 females and 36 males, with an average age of (44.5 ± 16.8) years old, ranging from 19 to 77 years. The clinical characteristics were mostly cough (49.2%), dyspnea (22.2%), hemoptysis (39.7%) and chest pain (39.7%). Kaplan‒Meier analysis showed that sex, age, hemoptysis, metastasis and treatment combining surgery with chemotherapy had a significant effect on survival. There were no effects on other outcomes. Furthermore, univariate and multivariable Cox regression analyses showed that the impact of the treatment combining surgery with chemotherapy on OS showed independent prognostic significance.
conclusionPPC is a rare disease that lacks specific clinical features. Early diagnosis with optimal management is a significant goal. Surgery followed by adjuvant chemotherapy may be the best treatment for PPC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.